(SMHN) SÜSS MicroTec SE - Overview
Stock: Mask Aligners, Coaters, Developers, UV Scanners, Bonders, Photomask Cleaners
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.78% |
| Yield on Cost 5y | 1.26% |
| Yield CAGR 5y | 23.31% |
| Payout Consistency | 99.0% |
| Payout Ratio | 14.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 68.2% |
| Relative Tail Risk | -18.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.45 |
| Alpha | 0.23 |
| Character TTM | |
|---|---|
| Beta | 0.579 |
| Beta Downside | 0.647 |
| Drawdowns 3y | |
|---|---|
| Max DD | 65.63% |
| CAGR/Max DD | 0.48 |
Description: SMHN SÜSS MicroTec SE December 25, 2025
SÜSS MicroTec SE (XETRA: SMHN) designs, manufactures and services equipment for microelectronics and MEMS production, operating through two segments: Advanced Backend Solutions (mask aligners, coaters, bonders for advanced packaging, 3D integration and compound semiconductors) and Photomask Solutions (cleaning and processing systems for semiconductor photomasks). The firm serves a global customer base across Europe, the Middle East, Africa, North America and the Asia-Pacific.
In FY 2023 the company reported revenue of roughly €1.2 billion, with an adjusted EBITDA margin near 15 % and an order backlog of about €300 million, indicating a moderate cushion against short-term demand swings. Its exposure to the fast-growing advanced packaging market-projected by industry analysts to expand at a CAGR of 12-15 % through 2028-represents a key upside driver.
Macro-level, semiconductor equipment capex is expected to rise 8-10 % YoY in 2024, buoyed by renewed investment in 3-D ICs and heterogeneous integration, which directly benefits SÜSS MicroTec’s backend product line. Conversely, the company remains sensitive to cyclical semiconductor demand and supply-chain constraints in key regions such as Taiwan and South Korea.
For a deeper dive into SMHN’s valuation metrics, the ValueRay platform offers a concise, data-driven overview.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 53.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.05 > 0.02 and ΔFCF/TA -10.22 > 1.0 |
| NWC/Revenue: 50.79% < 20% (prev 59.32%; Δ -8.52% < -1%) |
| CFO/TA -0.01 > 3% & CFO -6.32m > Net Income 53.0m |
| Net Debt (-43.9m) to EBITDA (93.5m): -0.47 < 3 |
| Current Ratio: 2.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (19.1m) vs 12m ago 0.71% < -2% |
| Gross Margin: 37.26% > 18% (prev 0.39%; Δ 3687 % > 0.5%) |
| Asset Turnover: 107.4% > 50% (prev 83.75%; Δ 23.61% > 0%) |
| Interest Coverage Ratio: 100.7 > 6 (EBITDA TTM 93.5m / Interest Expense TTM 836.0k) |
Altman Z'' 7.22
| A: 0.52 (Total Current Assets 413.3m - Total Current Liabilities 141.4m) / Total Assets 522.9m |
| B: 0.45 (Retained Earnings 237.3m / Total Assets 522.9m) |
| C: 0.17 (EBIT TTM 84.2m / Avg Total Assets 498.6m) |
| D: 1.14 (Book Value of Equity 248.4m / Total Liabilities 218.7m) |
| Altman-Z'' Score: 7.22 = AAA |
Beneish M -2.18
| DSRI: 1.62 (Receivables 97.0m/44.4m, Revenue 535.3m/397.2m) |
| GMI: 1.03 (GM 37.26% / 38.53%) |
| AQI: 0.90 (AQ_t 0.05 / AQ_t-1 0.05) |
| SGI: 1.35 (Revenue 535.3m / 397.2m) |
| TATA: 0.11 (NI 53.0m - CFO -6.32m) / TA 522.9m) |
| Beneish M-Score: -2.18 (Cap -4..+1) = BB |
What is the price of SMHN shares?
Over the past week, the price has changed by -6.95%, over one month by +5.03%, over three months by +53.89% and over the past year by +8.06%.
Is SMHN a buy, sell or hold?
What are the forecasts/targets for the SMHN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 54.9 | 18.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 54.7 | 18% |
SMHN Fundamental Data Overview February 03, 2026
P/E Trailing = 16.8746
P/S = 1.7777
P/B = 2.9215
Revenue TTM = 535.3m EUR
EBIT TTM = 84.2m EUR
EBITDA TTM = 93.5m EUR
Long Term Debt = 3.12m EUR (from longTermDebt, last quarter)
Short Term Debt = 6.46m EUR (from shortTermDebt, last quarter)
Debt = 50.5m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -43.9m EUR (from netDebt column, last quarter)
Enterprise Value = 907.7m EUR (951.6m + Debt 50.5m - CCE 94.4m)
Interest Coverage Ratio = 100.7 (Ebit TTM 84.2m / Interest Expense TTM 836.0k)
EV/FCF = -35.65x (Enterprise Value 907.7m / FCF TTM -25.5m)
FCF Yield = -2.80% (FCF TTM -25.5m / Enterprise Value 907.7m)
FCF Margin = -4.76% (FCF TTM -25.5m / Revenue TTM 535.3m)
Net Margin = 9.90% (Net Income TTM 53.0m / Revenue TTM 535.3m)
Gross Margin = 37.26% ((Revenue TTM 535.3m - Cost of Revenue TTM 335.8m) / Revenue TTM)
Gross Margin QoQ = 33.03% (prev 36.48%)
Tobins Q-Ratio = 1.74 (Enterprise Value 907.7m / Total Assets 522.9m)
Interest Expense / Debt = 1.01% (Interest Expense 509.0k / Debt 50.5m)
Taxrate = 24.81% (3.03m / 12.2m)
NOPAT = 63.3m (EBIT 84.2m * (1 - 24.81%))
Current Ratio = 2.92 (Total Current Assets 413.3m / Total Current Liabilities 141.4m)
Debt / Equity = 0.17 (Debt 50.5m / totalStockholderEquity, last quarter 304.2m)
Debt / EBITDA = -0.47 (Net Debt -43.9m / EBITDA 93.5m)
Debt / FCF = 1.72 (negative FCF - burning cash) (Net Debt -43.9m / FCF TTM -25.5m)
Total Stockholder Equity = 293.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.63% (Net Income 53.0m / Total Assets 522.9m)
RoE = 18.05% (Net Income TTM 53.0m / Total Stockholder Equity 293.6m)
RoCE = 28.37% (EBIT 84.2m / Capital Employed (Equity 293.6m + L.T.Debt 3.12m))
RoIC = 21.21% (NOPAT 63.3m / Invested Capital 298.5m)
WACC = 7.68% (E(951.6m)/V(1.00b) * Re(8.05%) + D(50.5m)/V(1.00b) * Rd(1.01%) * (1-Tc(0.25)))
Discount Rate = 8.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 0.04%
Fair Price DCF = unknown (Cash Flow -25.5m)
EPS Correlation: 57.71 | EPS CAGR: 7.19% | SUE: -0.42 | # QB: 0
Revenue Correlation: 84.46 | Revenue CAGR: 12.86% | SUE: -0.00 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.48 | Chg30d=-0.068 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=1.97 | Chg30d=-0.154 | Revisions Net=-1 | Growth EPS=-17.0% | Growth Revenue=-11.0%